Physician profile
Michael C Shaw
NPI 1235161936
$1,169.35
in general payments reported to CMS, 2019-2025
25 companies · $98.53 in 2025
The $98.53 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $81.51 · 2021: $175 · 2022: $151 · 2023: $238 · 2024: $166 · 2025: $98.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $451.94 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $185.42 | 2019-2025 | Evenity, Prolia |
| Currax Pharmaceuticals LLC | $110.43 | 2022-2023 | Nexletol, Nexlizet, Contrave |
| Lilly USA, LLC | $109.47 | 2019-2023 | Mounjaro |
| Janssen Pharmaceuticals, INC | $102.20 | 2021-2024 | Xarelto, Spravato |
| Abbvie INC. | $100.51 | 2021-2024 | |
| Astellas Pharma US INC | $65.15 | 2019 | |
| Pfizer INC. | $54.88 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $54.45 | 2019-2024 | Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.50 | 2019-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $49.60 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $38.32 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $37.44 | 2021-2022 | |
| Medtronic, INC. | $25.19 | 2021-2025 | Inceptiv |
| Abbott Laboratories | $24.83 | 2023 | Freestyle Libre 2 |
| Dexcom, INC. | $22.10 | 2024 | Dexcom G6 Transmitter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $16.71 | 2023 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $15.38 | 2022 | |
| Amarin Pharma, INC. | $14.79 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $14.70 | 2023 | Prehevbrio |
| Lucid Diagnostics INC. | $14.44 | 2022 | |
| Merck Sharp & Dohme LLC | $13.89 | 2020 | |
| Sanofi Pasteur INC. | $13.30 | 2019 | |
| Allergan, INC. | $11.36 | 2020 | |
| Horizon Therapeutics Plc | $11.35 | 2021 | |
| Sunovion Pharmaceuticals INC. | $10.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.